Kynurenine pathway

Last updated
The kynurenine pathway KP pathway.jpg
The kynurenine pathway

The kynurenine pathway is a metabolic pathway leading to the production of nicotinamide adenine dinucleotide (NAD+). [1] Metabolites involved in the kynurenine pathway include tryptophan, kynurenine, kynurenic acid, xanthurenic acid, quinolinic acid, and 3-hydroxykynurenine. [2] [3] The kynurenine pathway is responsible for about 95% of total tryptophan catabolism. [4] Disruption in the pathway is associated with certain genetic and psychiatric disorders. [5] [2] [6] [7] [8]

Contents

Kynurenine pathway dysfunction

Disorders affecting the kynurenine pathway may be primary (of genetic origin) or secondary (due to inflammatory conditions). [9] Peripheral inflammation can lead to a build up of kynurenine in the brain, and this is associated with major depressive disorder, [5] [6] bipolar disorder, [1] [5] [2] [8] and schizophrenia. [5] [7] [6] Dysfunction of the pathway not only causes increase in amounts of metabolites such as quinolinic acid and kynurenic acid but also affects synthesis of serotonin and melatonin. [10] Kynurenine clearance in exercised muscle cells can suppress the build up in the brain. [11] [12]

Hydroxykynureninuria

Also known as kynureninase deficiency, this extremely rare inherited disorder is caused by the defective enzyme kynureninase which leads to a block in the pathway from tryptophan to niacin (nicotinic acid). As a result, tryptophan is no longer a source of niacin, hence leading to pellagra (niacin deficiency). Both B6-responsive and B6-unresponsive forms are known. Patients with this disorder excrete excessive amounts of xanthurenic acid, kynurenic acid, 3-hydroxykynurenine, and kynurenine after tryptophan loading and are said to suffer from tachycardia, irregular breathing, arterial hypotension, cerebellar ataxia, developmental retardation, coma, renal tubular dysfunction, renal or metabolic acidosis, and even death. The only biochemical abnormality noted in affected patients was a massive hyperkynureninuria, seen only during periods of coma or after intravenous protein loading. This disturbance was temporarily corrected by large doses of vitamin B6. The activity of kynureninase in the liver was markedly reduced. The activity was appreciably restored by the addition of pyridoxal phosphate. [13] [14] [15] [16]

Acquired and inherited enzyme deficiencies

Downregulation of kynurenine 3-monooxygenase (KMO) can be caused by genetic polymorphisms, cytokines, or both. [17] [18] KMO deficiency leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenic acid and anthranilic acid. [19] [20] [21] [22] [23] [24]

Deficiencies of one or more enzymes on the kynurenine pathway leads to an accumulation of intermediate metabolic products which can cause effects depending on their concentration, function and their inter-relation with other metabolic products. [19] For example, kynurenine 3-monooxygenase deficiency is associated with disorders of the brain (such as schizophrenia and tic disorders) and of the liver. [22] [20] [21] [23] [24] The mechanism behind this observation is typically a blockade or bottleneck situation at one or more enzymes on the kynurenine pathway due to the effects of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) and/or due to genetic polymorphisms afflicting the particular genes. [19] [18] [25] [21] Dysfunctional states of distinct steps of the kynurenine pathway (such as kynurenine, kynurenic acid, quinolinic acid, anthranilic acid, 3-hydroxykynurenine) have been described for a number of disorders, for example: [26]

Research

Research into roles of the kynurenine pathway in human physiology is ongoing. [1]

Neurodegenerative diseases and mental disorders

Scientists are investigating the role of dysregulation of this pathway in aging, neurodegenerative diseases, mental disorders, somatic symptom disorders, and chronic fatigue syndrome (CFS). [30] [31] [32] [33] [2] [1]

Kynurenine/tryptophan ratio

Changes in the ratio of kynurenine versus tryptophan are reported for many diseases like arthritis, HIV/AIDS, neuropsychiatric disorders, [1] [6] [2] cancer and inflammations. [34] [35] [36] [37] The kynurenin/tryptophan is also an indicator for the activity of indoleamine 2,3-dioxygenase (IDO). [38] [39]

Methods

Kynurenine metabolites can be quantified using liquid chromatography coupled to mass spectrometry. [40]

In some species, the kynurenine pathway also processes 6-bromotryptophan, leading to the analogous series of brominated metabolites. These and subsequent derivatives are believed to be responsible for the biofluorescence observed in the skin of the swell shark and the chain catshark. [41]

Related Research Articles

<span class="mw-page-title-main">Tryptophan</span> Chemical compound

Tryptophan (symbol Trp or W) is an α-amino acid that is used in the biosynthesis of proteins. Tryptophan contains an α-amino group, an α-carboxylic acid group, and a side chain indole, making it a polar molecule with a non-polar aromatic beta carbon substituent. Tryptophan is also a precursor to the neurotransmitter serotonin, the hormone melatonin, and vitamin B3. It is encoded by the codon UGG.

<span class="mw-page-title-main">Leucine</span> Chemical compound

Leucine (symbol Leu or L) is an essential amino acid that is used in the biosynthesis of proteins. Leucine is an α-amino acid, meaning it contains an α-amino group (which is in the protonated −NH3+ form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO form under biological conditions), and a side chain isobutyl group, making it a non-polar aliphatic amino acid. It is essential in humans, meaning the body cannot synthesize it: it must be obtained from the diet. Human dietary sources are foods that contain protein, such as meats, dairy products, soy products, and beans and other legumes. It is encoded by the codons UUA, UUG, CUU, CUC, CUA, and CUG. Leucine is named after the Greek word for "white": λευκός (leukós, "white"), after its common appearance as a white powder, a property it shares with many other amino acids.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Tetrahydrobiopterin</span> Chemical compound

Tetrahydrobiopterin (BH4, THB), also known as sapropterin (INN), is a cofactor of the three aromatic amino acid hydroxylase enzymes, used in the degradation of amino acid phenylalanine and in the biosynthesis of the neurotransmitters serotonin (5-hydroxytryptamine, 5-HT), melatonin, dopamine, norepinephrine (noradrenaline), epinephrine (adrenaline), and is a cofactor for the production of nitric oxide (NO) by the nitric oxide synthases. Chemically, its structure is that of a (dihydropteridine reductase) reduced pteridine derivative (quinonoid dihydrobiopterin).

<span class="mw-page-title-main">Kynurenine</span> Chemical compound

l-Kynurenine is a metabolite of the amino acid l-tryptophan used in the production of niacin.

<span class="mw-page-title-main">Kynurenic acid</span> Chemical compound

Kynurenic acid is a product of the normal metabolism of amino acid L-tryptophan. It has been shown that kynurenic acid possesses neuroactive activity. It acts as an antiexcitotoxic and anticonvulsant, most likely through acting as an antagonist at excitatory amino acid receptors. Because of this activity, it may influence important neurophysiological and neuropathological processes. As a result, kynurenic acid has been considered for use in therapy in certain neurobiological disorders. Conversely, increased levels of kynurenic acid have also been linked to certain pathological conditions.

<span class="mw-page-title-main">Indoleamine 2,3-dioxygenase</span> Mammalian protein found in Homo sapiens

Indoleamine-pyrrole 2,3-dioxygenase (IDO or INDO EC 1.13.11.52) is a heme-containing enzyme physiologically expressed in a number of tissues and cells, such as the small intestine, lungs, female genital tract or placenta. In humans is encoded by the IDO1 gene. IDO is involved in tryptophan metabolism. It is one of three enzymes that catalyze the first and rate-limiting step in the kynurenine pathway, the O2-dependent oxidation of L-tryptophan to N-formylkynurenine, the others being indolamine-2,3-dioxygenase 2 (IDO2) and tryptophan 2,3-dioxygenase (TDO). IDO is an important part of the immune system and plays a part in natural defense against various pathogens. It is produced by the cells in response to inflammation and has an immunosuppressive function because of its ability to limit T-cell function and engage mechanisms of immune tolerance. Emerging evidence suggests that IDO becomes activated during tumor development, helping malignant cells escape eradication by the immune system. Expression of IDO has been described in a number of types of cancer, such as acute myeloid leukemia, ovarian cancer or colorectal cancer. IDO is part of the malignant transformation process and plays a key role in suppressing the anti-tumor immune response in the body, so inhibiting it could increase the effect of chemotherapy as well as other immunotherapeutic protocols. Furthermore, there is data implicating a role for IDO1 in the modulation of vascular tone in conditions of inflammation via a novel pathway involving singlet oxygen.

<span class="mw-page-title-main">Aromatic amino acid</span> Amino acid having an aromatic ring

An aromatic amino acid is an amino acid that includes an aromatic ring.

<i>N</i>-Formylkynurenine Chemical compound

N-Formylkynurenine is an intermediate in the catabolism of tryptophan. It is a formylated derivative of kynurenine. The formation of N-formylkynurenine is catalyzed by heme dioxygenases.

<span class="mw-page-title-main">Kynurenine 3-monooxygenase</span> Enzyme

In enzymology, a kynurenine 3-monooxygenase (EC 1.14.13.9) is an enzyme that catalyzes the chemical reaction

In enzymology, an indole 2,3-dioxygenase (EC 1.13.11.17) is an enzyme that catalyzes the chemical reaction

<span class="mw-page-title-main">Tryptophan 2,3-dioxygenase</span> Mammalian protein found in Homo sapiens

In enzymology, tryptophan 2,3-dioxygenase (EC 1.13.11.11) is a heme enzyme that catalyzes the oxidation of L-tryptophan (L-Trp) to N-formyl-L-kynurenine, as the first and rate-limiting step of the kynurenine pathway.

<span class="mw-page-title-main">Dioxygenase</span> Class of enzymes

Dioxygenases are oxidoreductase enzymes. Aerobic life, from simple single-celled bacteria species to complex eukaryotic organisms, has evolved to depend on the oxidizing power of dioxygen in various metabolic pathways. From energetic adenosine triphosphate (ATP) generation to xenobiotic degradation, the use of dioxygen as a biological oxidant is widespread and varied in the exact mechanism of its use. Enzymes employ many different schemes to use dioxygen, and this largely depends on the substrate and reaction at hand.

<span class="mw-page-title-main">Xanthurenic acid</span> Chemical compound

Xanthurenic acid, or xanthurenate, is a metabolic intermediate that accumulates and is excreted by pyridoxine (vitamin B6) deficient animals after the ingestion of tryptophan.

<span class="mw-page-title-main">Quinolinic acid</span> Dicarboxylic acid with pyridine backbone

Quinolinic acid, also known as pyridine-2,3-dicarboxylic acid, is a dicarboxylic acid with a pyridine backbone. It is a colorless solid. It is the biosynthetic precursor to niacin.

<span class="mw-page-title-main">KMO (gene)</span> Protein-coding gene in the species Homo sapiens

Kynurenine 3-monooxygenase is an enzyme that in humans is encoded by the KMO gene.

<span class="mw-page-title-main">Hypertryptophanemia</span> Medical condition

Hypertryptophanemia is a rare autosomal recessive metabolic disorder that results in a massive buildup of the amino acid tryptophan in the blood, with associated symptoms and tryptophanuria.

Pharmacometabolomics, also known as pharmacometabonomics, is a field which stems from metabolomics, the quantification and analysis of metabolites produced by the body. It refers to the direct measurement of metabolites in an individual's bodily fluids, in order to predict or evaluate the metabolism of pharmaceutical compounds, and to better understand the pharmacokinetic profile of a drug. Alternatively, pharmacometabolomics can be applied to measure metabolite levels following the administration of a pharmaceutical compound, in order to monitor the effects of the compound on certain metabolic pathways(pharmacodynamics). This provides detailed mapping of drug effects on metabolism and the pathways that are implicated in mechanism of variation of response to treatment. In addition, the metabolic profile of an individual at baseline (metabotype) provides information about how individuals respond to treatment and highlights heterogeneity within a disease state. All three approaches require the quantification of metabolites found in bodily fluids and tissue, such as blood or urine, and can be used in the assessment of pharmaceutical treatment options for numerous disease states.

Immuno-psychiatry, according to Pariante, is a discipline that studies the connection between the brain and the immune system. It differs from psychoneuroimmunology by postulating that behaviors and emotions are governed by peripheral immune mechanisms. Depression, for instance, is seen as malfunctioning of the immune system.

<span class="mw-page-title-main">Indoleamine 2,3-dioxygenase 2</span> Protein-coding gene in the species Homo sapiens

Indoleamine 2,3-dioxygenase 2 (IDO2) is a protein that in humans is encoded by the IDO2 gene.

References

  1. 1 2 3 4 5 6 Bartoli, F; Cioni, RM; Cavaleri, D; Callovini, T; Crocamo, C; Misiak, B; Savitz, JB; Carrà, G (11 November 2022). "The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview". European Psychiatry. 65 (1): e82. doi: 10.1192/j.eurpsy.2022.2340 . PMC   9724221 . PMID   36366795.
  2. 1 2 3 4 5 6 Bartoli, F; Misiak, B; Callovini, T; Cavaleri, D; Cioni, RM; Crocamo, C; Savitz, JB; Carrà, G (July 2021). "The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites". Molecular Psychiatry. 26 (7): 3419–3429. doi:10.1038/s41380-020-00913-1. PMID   33077852. S2CID   224314102.
  3. Savitz, J (25 January 2020). "The kynurenine pathway: a finger in every pie". Molecular Psychiatry. 25 (1): 131–147. doi:10.1038/s41380-019-0414-4. PMC   6790159 . PMID   30980044.
  4. Thomas, Sunil; Laury-Kleintop, Lisa; Prendergast, George C. (2019-01-01), "Chapter Twelve - Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues", in Galluzzi, Lorenzo; Rudqvist, Nils-Petter (eds.), Tumor Immunology and Immunotherapy – Molecular Methods, Methods in Enzymology, vol. 629, Academic Press, pp. 219–233, doi:10.1016/bs.mie.2019.08.008, PMID   31727242, S2CID   208037565 , retrieved 2022-04-12
  5. 1 2 3 4 5 6 7 8 Marx, Wolfgang; McGuinness, Amelia J.; Rocks, Tetyana; Ruusunen, Anu; Cleminson, Jasmine; Walker, Adam J.; Gomes-da-Costa, Susana; Lane, Melissa; Sanches, Marsal; Diaz, Alexandre P.; Tseng, Ping-Tao (August 2021). "The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies". Molecular Psychiatry. 26 (8): 4158–4178. doi:10.1038/s41380-020-00951-9. ISSN   1359-4184. PMID   33230205. S2CID   227132820.
  6. 1 2 3 4 5 Bartoli, F; Cioni, RM; Callovini, T; Cavaleri, D; Crocamo, C; Carrà, G (17 May 2021). "The kynurenine pathway in schizophrenia and other mental disorders: Insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites". Schizophrenia Research. 232: 61–62. doi:10.1016/j.schres.2021.04.008. PMID   34015557. S2CID   235074432.
  7. 1 2 3 Morrens, Manuel; De Picker, Livia; Kampen, Jarl K.; Coppens, Violette (September 2020). "Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis". Schizophrenia Research. 223: 43–52. doi:10.1016/j.schres.2020.09.007. ISSN   1573-2509. PMID   32981827. S2CID   221883723.
  8. 1 2 3 4 Arnone, Danilo; Saraykar, Smita; Salem, Haitham; Teixeira, Antonio L.; Dantzer, Robert; Selvaraj, Sudhakar (September 2018). "Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies". Neuroscience and Biobehavioral Reviews. 92: 477–485. doi:10.1016/j.neubiorev.2018.05.031. ISSN   1873-7528. PMC   6686193 . PMID   29940237.
  9. Davis, Ian; Liu, Aimin (2015). "What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?". Expert Review of Neurotherapeutics. 15 (7): 719–721. doi:10.1586/14737175.2015.1049999. ISSN   1744-8360. PMC   4482796 . PMID   26004930.
  10. Zoga, Margarita; Oulis, Panagiotis; Chatzipanagiotou, Stylianos; Masdrakis, Vasilios G.; Pliatsika, Paraskevi; Boufidou, Fotini; Foteli, Stefania; Soldatos, Constantin R.; Nikolaou, Chryssoula; Papageorgiou, Charalampos (July 2014). "Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females". In Vivo (Athens, Greece). 28 (4): 633–638. ISSN   1791-7549. PMID   24982234.
  11. Pedersen, BK (July 2019). "Physical activity and muscle-brain crosstalk". Nature Reviews. Endocrinology. 15 (7): 383–392. doi:10.1038/s41574-019-0174-x. PMID   30837717. S2CID   71143821.
  12. Cervenka, I; Agudelo, LZ; Ruas, JL (28 July 2017). "Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health". Science. 357 (6349): eaaf9794. doi: 10.1126/science.aaf9794 . PMID   28751584.
  13. Cheminal R, Echenne B, Bellet H, Duran M (1996). "Congenital non-progressive encephalopathy and deafness with intermittent episodes of coma and hyperkynureninuria". Journal of Inherited Metabolic Disease. 19 (1): 25–30. doi:10.1007/BF01799345. PMID   8830173. S2CID   810814.
  14. Komrower GM, Westall R (January 1967). "Hydroxykynureninuria". American Journal of Diseases of Children. 113 (1): 77–80. doi:10.1001/archpedi.1967.02090160127016. PMID   6015911.
  15. Salih MA, Bender DA, McCreanor GM (November 1985). "Lethal familial pellagra-like skin lesion associated with neurologic and developmental impairment and the development of cataracts". Pediatrics. 76 (5): 787–793. doi:10.1542/peds.76.5.787. PMID   4058988. S2CID   11014655.
  16. Tada K, Yokoyama Y, Nakagawa H, Yoshida T, Arakawa T (October 1967). "Vitamin B6 dependent xanthurenic aciduria". The Tohoku Journal of Experimental Medicine. 93 (2): 115–124. doi: 10.1620/tjem.93.115 . PMID   5586569.
  17. "Neurobiochemie und Psychopharmakologie" (in German). Klinikums der Universität München. Retrieved 26 May 2014.
  18. 1 2 Müller N, Myint AM, Schwarz MJ (February 2011). "Inflammatory biomarkers and depression". Neurotoxicity Research. 19 (2): 308–318. doi:10.1007/s12640-010-9210-2. PMID   20658274. S2CID   3225744.
  19. 1 2 3 Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK, Schwarcz R (July 2011). "Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes". Archives of General Psychiatry. 68 (7): 665–674. doi:10.1001/archgenpsychiatry.2011.71. PMC   3855543 . PMID   21727251.
  20. 1 2 Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen OA, Hall H, Terenius L, Agartz I, Jönsson EG, Schalling M, Erhardt S (January 2012). "Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls". Journal of Psychiatry & Neuroscience. 37 (1): 53–57. doi:10.1503/jpn.100175. PMC   3244499 . PMID   21693093.
  21. 1 2 3 Campbell BM, Charych E, Lee AW, Möller T (2014). "Kynurenines in CNS disease: regulation by inflammatory cytokines". Frontiers in Neuroscience. 8: 12. doi: 10.3389/fnins.2014.00012 . PMC   3915289 . PMID   24567701.
  22. 1 2 Hoekstra PJ, Anderson GM, Troost PW, Kallenberg CG, Minderaa RB (June 2007). "Plasma kynurenine and related measures in tic disorder patients". European Child & Adolescent Psychiatry. 16 (Suppl 1): 71–77. doi:10.1007/s00787-007-1009-1. PMID   17665285. S2CID   39150343.
  23. 1 2 Buness A, Roth A, Herrmann A, Schmitz O, Kamp H, Busch K, Suter L (2014). "Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity". PLOS ONE. 9 (5): e97249. Bibcode:2014PLoSO...997249B. doi: 10.1371/journal.pone.0097249 . PMC   4023975 . PMID   24836604.
  24. 1 2 Hirata Y, Kawachi T, Sugimura T (October 1967). "Fatty liver induced by injection of L-tryptophan". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 144 (2): 233–241. doi:10.1016/0005-2760(67)90153-1. PMID   4168935.
  25. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpé S (September 2002). "Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation". Life Sciences. 71 (16): 1837–1848. doi:10.1016/s0024-3205(02)01853-2. PMID   12175700.
  26. Stone TW (June 2001). "Kynurenines in the CNS: from endogenous obscurity to therapeutic importance". Progress in Neurobiology. 64 (2): 185–218. doi:10.1016/s0301-0082(00)00032-0. PMID   11240212. S2CID   6446144.
  27. Cavaleri D, Crocamo C, Morello P, Bartoli F, Carrà G (January 2024). "The Kynurenine Pathway in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Blood Concentrations of Tryptophan and Its Catabolites". Journal of Clinical Medicine. 13 (2): 583. doi: 10.3390/jcm13020583 . PMC   10815986 . PMID   38276089.
  28. Lucette, A. Cysiq (2022). "Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study". medRxiv   10.1101/2022.06.07.22276020v1 .
  29. Davis HE, McCorkell L, Vogel JM, Topol EJ (2023). "Long COVID: major findings, mechanisms and recommendations". Nature Reviews Microbiology . 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. PMC   9839201 . PMID   36639608.
  30. Dogrul, Bekir Nihat (2022-03-01). "Indolamine 2,3-dioxygenase (IDO) inhibitors as a potential treatment for somatic symptoms". Medical Hypotheses. 160: 110777. doi:10.1016/j.mehy.2022.110777. ISSN   0306-9877. S2CID   246354945.
  31. Blankfield, Adele (2013-07-21). "Article Commentary: Kynurenine Pathway Pathologies: Do Nicotinamide and Other Pathway Co-Factors have a Therapeutic Role in Reduction of Symptom Severity, Including Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM)". International Journal of Tryptophan Research. 6s1 (Suppl 1): 39–45. doi:10.4137/IJTR.S11193. PMC   3729338 . PMID   23922501.
  32. van der Goot AT, Nollen EA (June 2013). "Tryptophan metabolism: entering the field of aging and age-related pathologies". Trends in Molecular Medicine. 19 (6): 336–344. doi: 10.1016/j.molmed.2013.02.007 . PMID   23562344.
  33. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (July 2012). "Kynurenines in the mammalian brain: when physiology meets pathology". Nature Reviews. Neuroscience. 13 (7): 465–477. doi:10.1038/nrn3257. PMC   3681811 . PMID   22678511.
  34. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M (April 1998). "Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients". Clinical Chemistry. 44 (4): 858–862. doi: 10.1093/clinchem/44.4.858 . PMID   9554499.
  35. Schroecksnadel K, Kaser S, Ledochowski M, Neurauter G, Mur E, Herold M, Fuchs D (September 2003). "Increased degradation of tryptophan in blood of patients with rheumatoid arthritis". The Journal of Rheumatology. 30 (9): 1935–1939. PMID   12966593.
  36. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K (March 2010). "Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer". Lung Cancer (Amsterdam, Netherlands). 67 (3): 361–365. doi:10.1016/j.lungcan.2009.05.001. PMID   19487045.
  37. Millischer, Vincent; Heinzl, Matthias; Faka, Anthi; Resl, Michael; Trepci, Ada; Klammer, Carmen; Egger, Margot; Dieplinger, Benjamin; Clodi, Martin; Schwieler, Lilly (2021-07-17). "Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial". Journal of Neuroinflammation. 18 (1): 158. doi: 10.1186/s12974-021-02196-x . ISSN   1742-2094. PMC   8286561 . PMID   34273987.
  38. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (December 1997). "Simultaneous measurement of serum tryptophan and kynurenine by HPLC". Clinical Chemistry. 43 (12): 2424–2426. doi: 10.1093/clinchem/43.12.2424 . PMID   9439467.
  39. Fuchs D, Möller AA, Reibnegger G, Stöckle E, Werner ER, Wachter H (1990). "Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms". Journal of Acquired Immune Deficiency Syndromes. 3 (9): 873–876. PMID   2166783.
  40. Midttun, Øivind; Hustad, Steinar; Ueland, Per M. (2009). "Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry". Rapid Communications in Mass Spectrometry. 23 (9): 1371–1379. Bibcode:2009RCMS...23.1371M. doi:10.1002/rcm.4013. ISSN   1097-0231. PMID   19337982.
  41. Park, Hyun Bong; Lam, Yick Chong; Gaffney, Jean P.; Weaver, James C.; Krivoshik, Sara Rose; Hamchand, Randy; Pieribone, Vincent; Gruber, David F.; Crawford, Jason M. (2019). "Bright Green Biofluorescence in Sharks Derives from Bromo-Kynurenine Metabolism". iScience. 19: 1291–1336. Bibcode:2019iSci...19.1291P. doi: 10.1016/j.isci.2019.07.019 . PMC   6831821 . PMID   31402257.